Acutus Medical : Corporate Presentation

Acutus Medical, Inc. (AFIB)

Corporate Presentation

Disclaimer

This presentation will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, the scope, progress, results and costs of developing our products or any other future products, the potential market size and size of the potential patient populations for our products, the timing and likelihood of success of obtaining product approvals, plans and objectives of management for future operations, the scope of protection we are able to establish and maintain for intellectual property rights covering our products, and future results of anticipated products, are forward- looking statements.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. Factors that may cause results to differ from these forward-looking statements are discussed under the Forward-Looking Statements section in the company's most recent 10K and other periodic filings with the Securities and Exchange Commission (SEC).

Any forward-looking statements provided during this presentation, including projections for future performance, are

based on management's expectations as of today. Acutus undertakes no obligation to update these statements, except

as required by applicable law.

2

Leading the Charge in Electrophysiology

We are a therapy management company

developing comprehensive and innovative technologies

to treat complex cardiac arrythmias

Our vision is to become the partner-of-choice to electrophysiologists

through our broad portfolio of diagnostic and therapy solutions

3

Our Markets are Large, Growing, and Underpenetrated

Key drivers: Growing incidence and	Market is projected to grow double-digits
diagnosis of cardiac arrhythmias	from 2018 to 20251

$ in millions

2018-2025 CAGR: ~11%

Western lifestyle	Rising utilization of
	self-monitoring devices

Progressive disease,	Well-established
reimbursement in
function of aging
developed markets

1. Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0062, June 2020
2. Total prevalence pool of ~53M with ~972K treated in 2020 and 1.04M in 2019

Despite nearly ~1 million procedures in 2020…

the market is under 5% penetrated2

4

Unique Electrophysiology Platform

AcQMap is the only system on the market designed specifically for the complex patient population

Non-Contact

3D Imaging & Mapping Catheter

Multi-modal

Guidance Console

Open Platform Compatible with

most EP Catheters

.035"

guidewire

48 Ultrasound	48 High Fidelity
Sensors
Electrodes

Comprehensive end-to-end suite of mapping, diagnostics, and therapy portfolio

5